Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. AptaPharma Inc.
EIR
•AptaPharma Inc.•March 16, 2018

AptaPharma Inc. – FDA EIR, Mar 16, 2018

Record Details

An FDA pre-approval inspection of Apta Pharma Inc. in Pennsauken, NJ, was conducted from March 6 to March 16, 2018. This inspection focused on Abbreviated New Drug Application (ANDA) 210602 for Ibuprofen 100mg Suspension, covering quality, laboratory, production, equipment, facility, material, and packaging/labeling systems. The inspection identified several deficiencies, documented in an FDA Form 483. Key issues included incomplete laboratory records for reference standard testing and standardization, and inadequate control procedures for monitoring and validating manufacturing processes to ensure consistent product characteristics. Additionally, the company lacked a robust system to track drug product distribution for potential recalls and failed to adequately control electronic data to prevent alteration or deletion. Verbal observations noted inaccurate statements of fact and errors within the regulatory submission itself. Management, including the Director of Quality and Vice Presidents, acknowledged these observations and committed to implementing corrective actions. These actions include providing a written response to the FDA, completing process validation for commercial batches, chemically analyzing product uniformity, and finalizing product labeling with distributor information to ensure proper post-market reporting and recall capabilities. The inspection underscored the need for enhanced control over data integrity and manufacturing processes to meet regulatory requirements.

Company
AptaPharma Inc.
Inspection date
March 16, 2018
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Frederick Razzaghi (Advisor)
  • Rakesh Lad (company_representative)
  • Siva Rama Krishna Nutalapati (recipient)
  • Yogesh Desai (company_representative)
View Company Profile

ID · 1dda210d-9101-42ce-aca7-33184b05f30e

Violation Codes2
21 CFR 820.10021 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for AptaPharma Inc.
  • 483 - 2026-08-14August 14, 2026
  • 483 - 2023-05-15May 15, 2023
  • EIR - 2019-09-25September 25, 2019
  • 483 - 2019-09-25September 25, 2019
  • 483 - 2018-03-16March 16, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AptaPharma Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.